Efficacy of Azithromycin and Meropenem in Pediatric XDR Salmonella Typhi: A Retrospective Study from Abbottabad, Pakistan

Authors

  • Khyal Muhammad Department of Pediatrics, Ayub Teaching Hospital Complex, Abbottabad, Pakistan.
  • Kalsoom Abbottabad International Medical College, Pakistan.
  • Amna Khan Abbottabad International Medical College, Pakistan.
  • Anis Ur Rehman Abbottabad International Medical College, Pakistan.
  • Khadija Bibi Rehman Medical College, Peshawar, Pakistan.

Keywords:

Antibiotic Resistance, Azithromycin, Meropenem, Salmonella Typhi, Typhoid Fever

Abstract

Objective: To evaluate the efficacy of azithromycin as a first-line therapy and the combination of meropenem and azithromycin as the second-line therapy in treating pediatric patients with extensively drug-resistant (XDR) Salmonella Typhi in Abbottabad, Pakistan.
Methods: This retrospective cross-sectional study was conducted at Department of Pediatrics, Abbottabad International Medical Complex, Pakistan from May 2022 to January 2024. Children aged 1-15 years clinically diagnosed with typhoid fever were enrolled if subsequent blood cultures confirmed XDR Salmonella Typhi infection. Initial treatment comprised azithromycin. If there was no response to azithromycin, patients received a combination therapy of meropenem alongside continued azithromycin. Primary outcomes were clinical recovery, recurrence within 30 days post-treatment, and treatment-related adverse effects.
Results: Of total 67 pediatric patients, the mean age of the patients was 10.02 ±2.76 years. The overall mean duration of defervescence was 6.01 ±2.98 days. Initially, all patients were treated with azithromycin alone. Most patients recovered clinically 57 (85.1%). For the 10 (14.9%) who did not respond, meropenem was added to azithromycin, resulting in recovery for all. The mean duration of defervescence found significantly low in patients who received azithromycin monotherapy as compared to patients who received combination therapy i.e., 4.80 ±0.58 days vs. 12.90 ±1.10 days (p-value <0.001). Mild nausea was the only adverse event observed in 29 patients (43.3%) during treatment.
Conclusion: Azithromycin monotherapy demonstrated a high clinical recovery rate, with a significant reduction in fever duration compared to combination therapy with meropenem. Mild nausea was the only treatment-related adverse effect observed.

Downloads

Download data is not yet available.

References

World Health Organization. Typhoid [Internet]. 2023 [cited 2024 May 17]. Available from: https://www. who.int/news-room/fact-sheets/detail/typhoid

Imran H, Saleem F, Gull S, Khan Z. Uncovering the grow-ing burden of enteric fever: A molecular analysis of Salmonella Typhi antimicrobial resistance. Microb Pathog 2024; 191:106676. doi:10.1016/j.micpath.2024.106676

Marchello CS, Carr SD, Crump JA. A systematic review on antimicrobial resistance among Salmonella Typhi worldwide. Am J Trop Med Hyg 2020; 103:2518-27. doi:10.4269/ajtmh.20-0258

Kim C, Latif I, Neupane DP, Lee GY, Kwon RS, Batool A, et al. The molecular basis of extensively drug-resistant Salmonella Typhi isolates from pediatric septicemia patients. PLoS One 2021; 16:e0257744. doi:10.1371/journal.pone.0257744

Wong VK, Baker S, Pickard DJ, Parkhill J, Page AJ, Feasey NA, et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events. Nat Genet 2015; 47:632-9. doi:10.1038/ng.3281

Baig U, Mehdi SM, Iftikhar N. A pattern of antibiotic drug resistance of Salmonella Typhi and Salmonella Paratyphi among children with enteric fever in a tertiary care hospital in Lahore, Pakistan. Croat Med J 2023; 64:256-64. doi:10.3325/cmj.2023.64.256

Zakir M, Khan M, Umar MI, Murtaza G, Ashraf M, Shamim S. Emerging trends of multidrug-resistant (mdr) and extensively drug-resistant (xdr) salmonella typhi in a tertiary care hospital of lahore, pakistan. Microorganisms 2021; 9:2484. doi:10.3390/microorganisms9122484

Qureshi S, Naveed AB, Yousafzai MT, Ahmad K, Ansari S, Lohana H, et al. Response of extensively drug resistant Salmonella Typhi to treatment with meropenem and azithromycin, in Pakistan. PLoS Negl Trop Dis 2020; 14:e0008682. doi:10.1371/journal.pntd.0008682

Qamar FN, Yousafzai MT, Khalid M, Kazi AM, Lohana H, Karim S, et al. Outbreak investigation of ceftriaxone-resistant Salmonella enterica serotype Typhi and its risk factors among the general population in Hyderabad, Pakistan: A matched case-control study. Lancet Infect Dis 2018; 18:1368-76. doi:10.1016/S1473-3099(18)30483-3

Batool R, Qureshi S, Yousafzai MT, Kazi M, Ali M, Qamar FN. Risk factors associated with extensively drug-resistant typhoid in an outbreak setting of lyari town karachi, Pakistan. Am J Trop Med Hyg 2022; 106:1379-83. doi:10.4269/ajtmh.21-1323

Shahid S, Mahesar M, Ghouri N, Noreen S. A review of clinical profile, complications and antibiotic susceptibility pattern of extensively drug-resistant (XDR) Salmonella Typhi isolates in children in Karachi. BMC Infect Dis 2021; 21:900. doi:10.1186/s12879-021-06599-2

Ishaque S, Syed B, Dodani SK, Anwar S. Comparison of single vs combination drug therapy in extensively drug resistant salmonella typhi: an observational study from Pakistan. Infect Drug Resist 2022; 15:6093-6100. doi:10.2147/IDR.S372136

Aslam A, Kharal SA, Aslam M, Raza A. Trends of antimicrobial resistance in typhoidal strains of salmonella in a tertiary care hospital in Pakistan. Cureus 2021; 13:e12664. doi:10.7759/cureus.12664

Carey ME, Dyson ZA, Ingle DJ, Amir A, Aworh MK, Chattaway MA, et al. Global typhoid genomics consortium group authorship. Global diversity and antimicrobial resistance of typhoid fever pathogens: Insights from a meta-analysis of 13,000 Salmonella Typhi genomes. Elife 2023; 12:e85867. doi:10.7554/eLife.85867

Shah SA, Nadeem M, Syed SA, Abidi FT, Khan N, Bano N. Antimicrobial sensitivity pattern of salmonella typhi: emergence of resistant strains. Cureus 2020; 12:e11778. doi:10.7759/cureus.11778

Rahim F, Amin S, Noor M, Naeem M, Bangash A. Extensively drug-resistant typhoid fever; it's not that simple: A case report. J Pak Med Assoc 2023; 73:1320-2. doi:10.47391/JPMA.6918

Langah A, Nadeem MC, Radhan AH, Asif M. Defervescence period of azithromycin versus ceftriaxone in children with enteric fever. Khyber Med Univ J 2020; 12:192-6. doi:10.35845/kmuj.2020.19085

Izhar K, Ahmed K, Rehan M, Umar M, Ikram N, Izhar NA, et al. Extensively drug-resistant Salmonella Typhi XDR infection at Rawalpindi medical university and allied hospitals. J Rawal Med Coll 2020; 24:406-11. doi:10.37939/jrmc.v24i4.1493

Frenck RW Jr, Nakhla I, Sultan Y, Bassily SB, Girgis YF, David J, et al. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. Clin Infect Dis 2000; 31:1134-8. doi:10.1086/317450

Anwar T, Rais H, Jamil MF, Safdar S, Amir MR, Altaf A, et al. Extended drug resistance in children with typhoid fever. Professional Med J 2020; 27:581-7. doi:10.29309/TPMJ/2020.27.3.3695

Downloads

Published

2024-08-09

How to Cite

Muhammad, K., Kalsoom, Khan, A., Rehman, A. U., & Bibi, K. (2024). Efficacy of Azithromycin and Meropenem in Pediatric XDR Salmonella Typhi: A Retrospective Study from Abbottabad, Pakistan. Journal of the Dow University of Health Sciences (JDUHS), 18(2), 84–90. Retrieved from https://mail.jduhs.com/index.php/jduhs/article/view/2193

Issue

Section

Original Articles